{"disease":{"id":"haemophilus-influenzae-type-b-infection","name":"haemophilus influenzae type b infection"},"drugs":{"marketed":[{"drug_id":"cefotaxime","indication_name":"Haemophilus Influenzae Type B Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxon","indication_name":"Haemophilus Influenzae Type B Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ceftriaxone","indication_name":"Haemophilus Influenzae Type B Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03870061","title":"Evaluation of an Infant Immunization Encouragement Program in Nigeria","phase":"NA","overall_status":"COMPLETED","enrollment_count":5187,"lead_sponsor_name":"GiveWell","has_results":false},{"nct_id":"NCT04056728","title":"A Phase IV Study to Assess the Safety of EupentaTM Inj","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"LG Chem","has_results":false},{"nct_id":"NCT04177485","title":"Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda","phase":"NA","overall_status":"COMPLETED","enrollment_count":1962,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT05457946","title":"Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":1438,"lead_sponsor_name":"LG Chem","has_results":false},{"nct_id":"NCT06618196","title":"Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":336,"lead_sponsor_name":"LG Chem","has_results":false},{"nct_id":"NCT04978818","title":"Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":333,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":true},{"nct_id":"NCT05952596","title":"A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"LG Chem","has_results":false},{"nct_id":"NCT03208101","title":"A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"LG Chem","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}